Omega Therapeutics, Inc. (OMGA)

2,0300 -0,0700 (-3,33%) Alla chiusura: 04:00PM EDT

Omega Therapeutics, Inc.

20 Acorn Park Drive
Cambridge, MA 02140
United States
617 949 4360
https://omegatherapeutics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 93

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Mahesh Karande	President, CEO & Board Director	910,39k	N/D	1974
Ms. Barbara Y. Chan	Principal Financial Office, Principal Accounting Officer & Chief Accounting Officer	N/D	N/D	1964
Dr. Thomas McCauley Ph.D.	Chief Scientific Officer	588,5k	N/D	1969
Ms. Eva Stroynowski	Senior Vice President of Investor Relations & Corporate Affairs	N/D	N/D	N/D
Mr. Anthony Mullin	Chief People Officer	N/D	N/D	N/D
Mr. Charles O'Donnell Ph.D.	VP and Head of Computational Genomics & Data Sciences	N/D	N/D	N/D
Dr. Kaan Certel Ph.D.	Chief Business Officer	N/D	N/D	N/D
Ms. Lisamarie Fahy	Senior Vice President of Clinical Development Operations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Omega Therapeutics, Inc. al 1 giugno 2024 è 9. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 10; diritti degli azionisti: 9; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.